NeuroVive Pharmaceutical AB Institutionelles Eigentum
Was ist das Institutionelles Eigentum von NeuroVive Pharmaceutical AB?
Institutionelles Eigentum von NeuroVive Pharmaceutical AB ist 48.96%
Was ist die Definition von Institutionelles Eigentum?
Institutionelles Eigentum ist der Betrag der verfügbaren Aktien eines Unternehmens, das sich im Besitz von Investmentfonds oder Pensionskassen, Versicherungsgesellschaften, Wertpapierfirmen, Stiftungen oder anderen großen Körperschaften befindet, die Fonds für Dritte verwalten.
Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.
Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.
Institutionelles Eigentum von Unternehmen in Health Care Sektor auf OTC im Vergleich zu NeuroVive Pharmaceutical AB
Was macht NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Unternehmen mit institutionelles eigentum ähnlich NeuroVive Pharmaceutical AB
- BNP Paribas Easy - Equity Low Vol Europe hat Institutionelles Eigentum von 48.91%
- BCE hat Institutionelles Eigentum von 48.94%
- Colony Bankcorp hat Institutionelles Eigentum von 48.94%
- First Trust Senior Floating Rate 2022 Target Term Fund hat Institutionelles Eigentum von 48.94%
- Gladstone Land Corp hat Institutionelles Eigentum von 48.95%
- Anworth Mortgage Asset hat Institutionelles Eigentum von 48.96%
- NeuroVive Pharmaceutical AB hat Institutionelles Eigentum von 48.96%
- Risanamento SpA hat Institutionelles Eigentum von 48.97%
- ClearBridge MLP and Midstream Total Return Fund Inc hat Institutionelles Eigentum von 48.99%
- Kitron ASA hat Institutionelles Eigentum von 49.00%
- Omeros hat Institutionelles Eigentum von 49.00%
- NorZinc hat Institutionelles Eigentum von 49.00%
- NorZinc hat Institutionelles Eigentum von 49.00%